3 completed, 3 recruiting, 2 terminated. 4 Phase 2, 3 Phase 1, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Terminated 2, Completed 1, Recruiting 1 |
| Phase 1 | 3 | Completed 1, Recruiting 1, Terminated 1 |
| Early Phase 1 | 1 | Completed 1 |
Follow John Kirkwood: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma Axelopran, Nivolumab - Unresectable Cutaneous Melanoma | Phase 1 / Phase 2 | Recruiting | John Kirkwood | 28 | 2026-11-30 | 2026-10-19 |
| Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma Fianlimab + Cemiplimab, Relatlimab + Nivolumab - Locally Advanced Melanoma | Recruiting | John Kirkwood | 20 | 2025-11-19 | 2025-11-26 | |
| Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi Single agent, adjuvant anti-PD1 therapy - Melanoma | Recruiting | John Kirkwood | 30 | 2025-02-20 | 2026-01-26 | |
| Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma Nivolumab, Duvelisib - Unresectable Melanoma | Phase 1 / Phase 2 | Terminated | John Kirkwood | 13 | 2021-10-06 | 2025-12-17 |
| Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting Relatlimab, Nivolumab, Relatlimab + Nivolumab - Melanoma | Phase 2 | Completed | John Kirkwood | 43 | 2019-03-29 | 2026-08-31 |
| Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma High-dose Interferon alfa-2b, Vemurafenib - Melanoma | Phase 1 | Completed | John Kirkwood | 7 | 2013-10-01 | 2018-04-03 |
| Pilot Study Evaluating Sulforaphane in Atypical Nevi-Precursor Lesions broccoli sprout extract - sulforaphane (BSE-SFN) - Atypical Nevi, Melanoma | Early Phase 1 | Completed | John Kirkwood | 17 | 2012-08-01 | 2018-01-09 |
| Dendritic Cells (DC) Vaccine for Metastatic Melanoma Vaccination - Metastatic Melanoma | Phase 2 | Terminated | John Kirkwood | 16 | 2002-10-01 | 2017-08-16 |
Melanoma (5) · Dysplastic Nevus Syndrome (2) · Hereditary Sensory and Autonomic Neuropathies (1)
Nivolumab (5) · relatlimab (2) · Axitinib (1) · Interferon alpha-2 (1) · Opdualag (1) · Pharmaceutical Preparations (1) · Vaccination (1) · Vemurafenib (1) · cemiplimab (1) · duvelisib (1) · pembrolizumab (1)
United States (8)
P01CA073743 (1)